Coronary/Structural Heart

Morton Plant First in Florida to Participate in Trial to Expand TAVR to Aortic Regurgitation Patients

 CLEARWATER, Fla., Feb. 1, 2023 /PRNewswire/ — The team at the Center for Advanced Valve and Structural Heart Care at BayCare’s Morton Plant Hospital achieved another first when they used the minimally invasive Transcatheter Aortic Valve Replacement (TAVR) procedure to treat a patient suffering from aortic regurgitation. The team led by Joshua Rovin, […]

Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF)

Patent is expected to provide additional intellectual property protection until 2040 Prevalence estimates indicate that PH-HFpEF affects over 1,500,000 patients in the U.S. There are currently no FDA approved treatments for PH-HFpEF CHAPEL HILL, N.C., Feb. 01, 2023 (GLOBE NEWSWIRE) — Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused […]

Conformal Medical Announces Positive One-Year Data from its Left Atrial Appendage Closure Performed Under Conscious Sedation Study

Data to be presented on February 3rd during a Spotlight Session at AF Symposium 2023 NASHUA, N.H., Jan. 31, 2023 /PRNewswire/ — Conformal Medical, Inc. announced today the presentation of the one-year data from the company’s initial left atrial appendage occlusion (LAAO) cases with its novel CLAAS® System in patients under conscious sedation without general anesthesia. […]

It Might Be the End of Open-Heart Surgeries: Israeli Biomed Company TruLeaf Medical Will Implant a Mitral Heart Valve via Two Needle Sticks only in a Two-Stage Catheterization Without Surgery

CAESAREA, Israel, Feb. 1, 2023 /PRNewswire/ —  AllMeD Solutions (TASE: ALMD) announced subsidiary TruLeaf Medical’s receipt of the Helsinki Ethics Committee’s approval to conduct clinical trial in human subjects As part of the trial, a prosthetic mitral valve will be implanted via two needle sticks in the groins in a two-stage catheterization procedure without the need for […]

BioCardia and CellProthera Enhance Collaboration for Development of ProtheraCytes™ for the Treatment of Acute Myocardial Infarction in Europe and Potential Early Access for Patients

SUNNYVALE, Calif. and MULHOUSE, France, Feb. 01, 2023 (GLOBE NEWSWIRE) — BioCardia, Inc. [Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, and CellProthera, a private developer of cell-based therapies to repair ischemic tissues, today announce an amendment to their Clinical Research Supply and Support […]

Sequana Medical announces grant of additional DSR® patent in United States

Ghent, Belgium – 1 February 2023 – Sequana Medical NV (Euronext Brussels: SEQUA) (the “Company” or “Sequana Medical“), a pioneer in the treatment of fluid overload in liver disease, heart failure and cancer, today announces the grant of an additional US patent for its DSR (Direct Sodium Removal) program. US patent number 11,559,618 B2 has been granted on 24 […]

CIS Launches National Cardiology Platform in Partnership With Lee Equity Partners

HOUMA, La.–(BUSINESS WIRE)–Cardiovascular Institute of the South (CIS), one of the largest independent cardiovascular practices in the country, announced the launch of a national cardiovascular platform, Cardiovascular Logistics, in partnership with private equity firm Lee Equity Partners, headquartered in New York City. The launch of Cardiovascular Logistics will build and […]

Bayer Partners with Huma on Bayer® Aspirin Heart Risk Assessment Online Educational Tool to Raise Awareness of Heart Health and its Risk Factors

Huma’s predictive algorithm will power a new global online patient engagement tool* that provides an accessible solution for heart health education NEW YORK, Feb. 1, 2023 /PRNewswire/ — Huma Therapeutics Limited (“Huma”), a leading global digital health company, and Bayer, a leading global life sciences company, have partnered to develop the Bayer Aspirin […]

Occlutech Continues its Progress in US FDA Study OCCLUFLEX – Enrolls First Patient in Europe

SCHAFFHAUSEN, CH / ACCESSWIRE / January 31, 2023 / Occlutech Holding AG Occlutech Holding AG (“Occlutech”), one of the world’s leading providers of minimally invasive structural heart disease devices, continues its progress in the US market. The first patient has now been enrolled in the global US study OCCLUFLEX in […]

Idorsia submits European marketing authorisation application for aprocitentan for the treatment of patients with resistant hypertension

The application includes data from the Phase 3 registration study of patients with resistant hypertension, where aprocitentan demonstrated a sustained blood pressure reduction over 48 weeks and was well-tolerated Allschwil, Switzerland – January 31, 2023 Idorsia Ltd (SIX: IDIA) today announced that it has submitted a marketing authorisation application (MAA) to the European […]